Survival of HER2-positive early breast cancer patients treated with intravenous adjuvant trastuzumab

Authors

Abstract

Introduction: The prognosis of HER2-positive breast cancer was very unfavorable before the use of trastuzumab. Use of this therapy in early stages improves the survival of patients receiving it.

Objective: Evaluate overall and disease-free survival.

Methods: An observational retrospective descriptive study was conducted which included all the HER2-positive breast cancer patients in early stages who underwent surgery and received intravenous adjuvant trastuzumab plus chemotherapy from January 2011 to December 2014. Overall and disease-free survival were analyzed. Toxicities were identified.

Results: A predominance was found of patients aged over 50 years with a history of hypertension, infiltrating ductal histology, vascular permeation, tumors larger than two centimeters, negative ganglia, grade 3 and positive hormone receptors. Greater use was observed of conservative surgery, ionizing radiation, hormone therapy and sequential chemotherapy. The relapse rate was similar to the one reported internationally, with bone and brain metastases as the most frequent. No clinical, histopathological or treatment variable was statistically significant for overall survival, whereas pathological antecedents, tumor size and nodal status were statistically significant for disease-free survival. Intravenous trastuzumab-related toxicities were scant, with cardiotoxicity as the most frequent. The vast majority of adverse events were classified as grade I-II.

Conclusions: Adjuvant treatment with intravenous trastuzumab plus chemotherapy improves overall and disease-free survival in HER2-positive early breast cancer patients, with a good safety profile.

Key words: early breast cancer, HER2-positive, adjuvant treatment, intravenous trastuzumab.

Downloads

Download data is not yet available.

Author Biographies

Iván Ramón Concepción, Hospital "Hermanos Ameijeiras"

Especialista de Oncología. Servicio de Oncología Clínica. Hospital Universitario "Hermanos Ameijeiras".

Jorge Luis Soriano García, Hospital "Hermanos Ameijeiras"

Jefe Departamento de Oncología. Profesor e Investigador Titular. Dr en Ciencias Médicas.

María de Lourdes Valenciano Estenoz, Hospital "Hermanos Ameijeiras"

Especialista en Oncología.

Noyde Batista Albuerne, Hospital "Hermanos Ameijeiras"

Especialista en Oncología.

Mayté Lima Pérez, Hospital "Hermanos Ameijeiras"

Especialista en Oncología.

Dayanis Duvergel Calderín, Hospital "Hermanos Ameijeiras"

Servicio de Anatomía Patológica.

María Caridad De Armas Fernández, Hospital "Hermanos Ameijeiras"

Servicio de Anatomía Patológica.

Jorge Lázaro Loys Fernández, Hospital "Hermanos Ameijeiras"

Servicio de Cirugía General.

Concepción Del Castillo Carrillo, Hospital "Hermanos Ameijeiras"

Servicio de Radioterapia.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin.2020;70:7-30. DOI:10.3322/caac.21590.

2. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA A Cancer J Clin.2019;69:438-51. DOI:10.3322/caac.21583.

3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.2018; 68(6):394-424. DOI:10.3322/caac.21492.

4. Anuario Estadístico de Cuba 2018. Edición 2019. MINSAP, Dirección Nacional de Registros Médicos y Estadísticas de Salud. La Habana. Versión electrónica. 2019 [acceso 30/10/2020]. https://files.sld.cu/bvscuba/files/2019/05/Anuario-Electrónico-Español-2018-ed-2019.pdf

5. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev.2018;27(6):619-26. DOI:10.1158/1055-9965.EPI-17-0627.

6. Maadi H, Nami B, Tong J. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer.2018;18:238. DOI:10.1186/s12885-018-4143-x.

7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science.1987;235(4785):177-82. DOI:10.1126/science.3798106.

8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med.2001;344(11):783-92. DOI:10.1056/NEJM200103153441101.

9. Patel A, Unni N, Peng Y. The changing paradigm for the treatment of HER2-Positive breast cancer. Cancers (Basel).2020;12(8):2081. DOI:10.3390/cancers12082081.

10. Wilson FR, Coombes ME, Brezden-Masley C. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Syst Rev.2018;7:191. DOI:10.1186/s13643-018-0854-y.

11. Fabiani I, Cipolla CM, Colombo N, Cardinale D. Cardioncological approach for trastuzumab therapy in breast cancer patients with cardiotoxicity: impact on adherence and clinical outcome. Front Pharmacol.2020;11:1190. DOI:10.3389/fphar.2020.01190.

12. Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, et al. De novo versus recurrent HER2-Positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs Registry. Oncologist. 2020;25:e214-e222. DOI:10.1634/theoncologist.2019-0446.

13. Soriano JL, Montejo N, Batista N, Loys J, Lima M, Castillo C, et al. Cáncer de mama en estadios tempranos. En: Soriano JL (Ed). Manual de Prácticas Médicas. Tomo 1 Unidad Funcional de Tumores. IV Edición. La Habana: Editorial de Ciencias Médicas; 2012. p. 21-89. ISBN: 978-959-212-786-9.

14. Lambertini M, Pondé NF, Solinas C, de Azambuja E. Adjuvant trastuzumab: a 10-year overview of its benefit. Expert Rev Anticancer Ther.2017;17:61-74. DOI:10.1080/14737140.2017.1264876.

15. Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCCPACS 04 trial. J Clin Oncol.2009;27:6129-34. DOI:10.1200/JCO.2009.23.0946.

16. Perez E, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol.2014;32:3744-52. DOI:10.1200/JCO.2014.55.5730.

17. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med.2005;353:1673-84. 2005. DOI:10.1056/NEJMoa052122.

18. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol.2011;29:3366-73. DOI:10.1200/JCO.2011.35.0868.

19. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet.2017;389:1195-1205. DOI:10.1016/S0140-6736(16)32616-2.

20. Slamon DJ, Eiermann W, Robert NJ. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (ACT) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients [abstract]. Cancer Res.2015;76(4suppl):S5-04. DOI:10.1158/1538-7445.SABCS15-S5-04.

21. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer trial. J Clin Oncol.2009;27:5685-92. DOI:10.1200/JCO.2008.21.4577.

22. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol.2019;37(22): 1868-75. DOI:10.1200/JCO.19.00066.

23. Álvarez I, Escobar X, Camacho R, Franco S, Armas MC, Ropero R, et al. Prevalencia del HER2 en el cáncer de mama en Cuba. Cancerología.2009;4:135-41. Disponible en: https://www.researchgate.net/publication/274711268_ Prevalencia_del_HER2_en_el_Cancer_de_Mama_en_Cuba

24. Duvergel C, Armas MC, Salvent A, Olivera E, Romero K. Caracterización histopatológica del cáncer de mama infiltrante HER2 positivo en el Hospital Hermanos Ameijeiras. Revista Cubana de Obstetricia y Ginecología. 2019; 45(4):e407.

25. Genuino AJ, Chaikledkaew U, The DO, Reungwetwattana T, Thakkinstian A. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. Expert Rev Clin Pharmacol.2019;12:815-24. DOI: 10.1080/17512433.2019.1637252.

26. Pathak M, Dwivedi SN, Deo SVS, Thakur B, Sreenivas V, Rath GK. Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. Syst Rev.2018;7(1):89. DOI:10.1186/s13643-018-0754-1.

27. Pathak M, Deo SV, Dwivedi SN, Thakur B, Sreenivas V, Rath GK. Regimens of neo-adjuvant chemotherapy in the treatment of breast cancer: A systematic review & network meta-analysis with PRISMA-NMA compliance. Crit Rev Oncol Hematol.2020;153:103015. DOI:10.1016/j.critrevonc.2020.103015.

28. Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, Pogue-Geile KL, et al. Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. J Clin Oncol.2019;37(35):3425-35. DOI:10.1200/JCO.19.00443.

29. Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget.2017;8(17):27990-6. DOI:10.18632/oncotarget.15856.

30. Moasser MM and Ai WZ. Neoplasia. In: Hammer GD and McPhee SJ, editors. Pathophysiology of Disease: An Introduction to Clinical Medicine. 8th edition. New York, NY: McGraw-Hill Education; 2019.

31. Gyawali B, Niraula S. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials. Cancer Treat Rev.2017;60:18-23. DOI:10.1016/j.ctrv.2017.08.001.

Downloads

Published

2021-06-02

How to Cite

1.
Ramón Concepción I, Soriano García JL, Valenciano Estenoz M de L, Batista Albuerne N, Lima Pérez M, Duvergel Calderín D, et al. Survival of HER2-positive early breast cancer patients treated with intravenous adjuvant trastuzumab. Rev Cub Oncol [Internet]. 2021 Jun. 2 [cited 2025 Nov. 8];19(1). Available from: https://revoncologia.sld.cu/index.php/onc/article/view/91

Issue

Vol. 19 No. 1 (2021): enero-abril

Section

Artículos Originales

License

Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.

Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.

El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.